Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19-Reference-Cited by-同舟云学术

Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19

Published:2020-01 Issue:1 Volume:7 Page:
ISSN:2053-9711
Container-title:Journal of Law and the Biosciences
language:en
Short-container-title:

Author:

Edmonds Sterling¹,MacGregor Andrea¹,Doll Agnieszka¹,Vural Ipek Eren¹²,Graham Janice³,Fierlbeck Katherine²,Lexchin Joel⁴,Doshi Peter⁵,Herder Matthew¹⁶

Affiliation:

1. Schulich School of Law, Dalhousie University

2. Department of Political Science, Dalhousie University

3. Department of Pediatrics (Infectious Diseases), Dalhousie University

4. School of Health Policy and Management, York University

5. Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy

6. Department of Pharmacology, Faculty of Medicine, Dalhousie University

Funder

Canadian Institutes of Health Research

Publisher

Oxford University Press (OUP)

Subject

Law,Biochemistry, Genetics and Molecular Biology (miscellaneous),Medicine (miscellaneous)

Link

http://academic.oup.com/jlb/advance-article-pdf/doi/10.1093/jlb/lsaa083/34398423/lsaa083.pdf

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The State of Patient-Reported Outcome Measures in Rheumatology;The Journal of Rheumatology;2024-06-01

2. “There's a little bit of mistrust”: Red River Métis experiences of the H1N1 and COVID‐19 pandemics;Risk Analysis;2024-01-29

3. How to use the regulatory data from Health Canada for secondary analyses on new drugs, biologics and vaccines;BMJ Evidence-Based Medicine;2023-10-28

4. Biopharmaceutical Financialization and Public Funding of Medical Countermeasures (MCMs) in Canada During the COVID-19 Pandemic;International Journal of Health Policy and Management;2023-05-27

5. On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data;Clinical Trials;2022-08-04